Q4 2015 13F Holders as of 12/31/2015
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
28.5M
-
Shares change
-
+721K
-
Total reported value, excl. options
-
$1.53B
-
Value change
-
+$51.7M
-
Put/Call ratio
-
2.57
-
Number of buys
-
74
-
Number of sells
-
-61
-
Price
-
$53.79
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2015
165 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q4 2015.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.5M shares
of 108M outstanding shares and own 26.46% of the company stock.
Largest 10 shareholders include FMR LLC (6.45M shares), VANGUARD GROUP INC (1.4M shares), TimesSquare Capital Management, LLC (1.32M shares), JENNISON ASSOCIATES LLC (1.26M shares), Redmile Group, LLC (1.22M shares), BlackRock Advisors LLC (1.2M shares), ADAGE CAPITAL PARTNERS GP LLC (1.08M shares), Visium Asset Management, LP (1M shares), MILLENNIUM MANAGEMENT LLC (949K shares), and BlackRock Fund Advisors (946K shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.